Overview on the Current Status of Available Test Methods and Additional Promising Methods for Assessing UV-Induced Effects
Photo-induced effects are based on the photosensitization processes by which a photosensitizer, i.e., a molecule absorbing nontoxic dose of ultraviolet (UV) or visible (VIS) radiation (chromophores), interacts with other molecules leading eventually to an adverse effect. The assessment of photo-induced toxicity is required when chemical preparations are intended to be used on sunlight-exposed skin, i.e., products topically applied to the skin or systemic drugs. It includes evaluation of phototoxic effects and of photoallergy, which will be discussed hereafter. Moreover, the recommended tiered phototoxic strategy, including nonbiological and biological assays, will be reported together with the ICH (International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) recommendations. In this photosafety strategy, UV/VIS spectral analysis should be employed as the first screening to indicate a potential phototoxic risk by measuring the molar extinction coefficient (MEC), followed by the ROS (reactive oxygen species) assay. The biological assays are then carried out to evaluate the phototoxic potential of those materials presenting potential phototoxic risk and include the 3T3 neutral red uptake phototoxicity test (3T3 NRU-PT) followed, if a positive result is obtained, by the human 3D reconstructed skin model phototoxicity test (H3D-PT). The last step is the confirmatory photopatch test to be applied to a group of volunteers and to be performed using the first non-phototoxic concentration determined in the H3D-PT using a margin of safety factor of 10. Finally, some epidemiological data regarding photoallergy will be presented.
- 1.ICH. Photosafety evaluation of pharmaceuticals S10. 2013. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S10/S10_Step_4.pdf. Accessed 8 Jul 2016.
- 3.Spielmann H, Muller L, Averbeck D, Balls M, Brendler-Schwaab S, Castell JV, Curren R, de Silva O, Gibbs NK, Liebsch M, Lovell WW, Merk HF, Nash JF, Neumann NJ, Pape WJW, Ulrich P, Vohr HW. The second ECVAM workshop on phototoxicity testing. ATLA. 2000;28:777–814.Google Scholar
- 5.JaCVAM. Reactive oxygen species (ROS) assay to examine photoreactivity of chemicals. 2013. http://www.jacvam.jp/files/doc/02_03/02_03_E2.pdf. Accessed 8 Jul 2016.
- 6.Onoue S, Hosoi K, Wakuri S, Iwase Y, Yamamoto T, Matsuoka N, Nakamura K, Toda T, Takagi H, Osaki N, Matsumoto Y, Kawakami S, Seto Y, Kato M, Yamada S, Ohno Y, Kojima H. Establishment and intra−/inter-laboratory validation of a standard protocol of reactive oxygen species assay for chemical photosafety evaluation. J Appl Toxicol. 2013;33:1241–50.Google Scholar
- 8.EMA. Questions and answers on the “Note for guidance of photosafety testing”. 2011. http://www.ema.europa.eu/ema/. Accessed 8 Jul 2016.
- 9.Ceridono M, Tellner P, Bauer D, Barroso J, Alépée N, Corvi R, De Smedt A, Fellows MD, Gibbs NK, Heisler E, Jacobs A, Jirova D, Jones D, Kandárová H, Kasper P, Akunda JK, Krul C, Learn D, Liebsch M, Lynch AM, Muster W, Nakamura K, Nash JF, Pfannerbecker U, Phillips G, Robles C, Rogiers V, Van de Water F, Liminga UW, Vohr HW, Wattrelos O, Woods J, Zuang V, Kreysa J, Wilcox P. The 3T3 neutral red uptake phototoxicity test: practical experience and implications for phototoxicity testing- the report of an ECVAM-EFPIA workshop. Regul Toxicol Pharmacol. 2012;63(3):480–8.CrossRefPubMedGoogle Scholar
- 10.OECD. OECD guidelines for the testing of chemicals, test no. 432: in vitro 3T3 NRU phototoxicity test. 2004. http://www.oecd.org/. Accessed 8 Jul 2016.
- 12.SCCS. SCCS/1564/15: the SCCS notes of guidance for the testing of cosmetic ingredients and their safety evaluation 9th revision, adopted by SCCS during the 11th plenary meeting of 29 September 2015 (revised version of 25 Apr 2016). 2016.Google Scholar
- 13.Liebsch M, Spielmann H. INVITTOX protocol No. 78: 3T3 NRU phototoxicity assay. European Commission DB-ALM, ECVAM. 2002. https://eurl-ecvam.jrc.ec.europa.eu. Accessed 8 Jul 2016.
- 14.Liebsch M. INVITTOX protocol No. 121: EpiDerm™ Phototoxicity assay. European Commission DB-ALM, ECVAM. 1999. https://eurl-ecvam.jrc.ec.europa.eu. Accessed 8 Jul 2016.
- 17.Kandárová H. Evaluation and validation of reconstructed human skin models as alternatives to animal tests in regulatory toxicology. Dissertation, Freie Universit ät Berlin, 2006.Google Scholar
- 19.Liebsch M, Traue D, Barrabas C, Spielmann H, Gerberick GF, Cruse L, Diembeck W, Pfannenbecker U, Spieker J, Hottzhutter H, Brantom P, Aspin P, Southee J. Prevalidation of the Epiderm™ phototoxicity test. In: Clark DG, Lisansky SG, Macmillan R, editors. Alternatives to animal testing II. Brussels: COLIPA; 1999. p. 160–7.Google Scholar
- 21.Dean JH, Luster MI, Munson AE, Kimber I, editors. lmmunotoxicology and immunopharmacology. New York: Raven Press; 1994.Google Scholar
- 23.OECD. OECD guideline for the testing of chemicals No. 442E: in vitro skin sensitisation: human cell line activation test (h-CLAT). Paris, France: Organisation for Economic Cooperation and Development. 2016. Available at http://www.oecd.org/env/testguidelines.
- 29.Lovell WW, Jones PA. Evaluation of mechanistic in vitro tests for the discrimination of photoallergic and photoirritant potential. Altern Lab Anim. 2000;28(5):707–24.Google Scholar
- 30.Bryden AM, Moseley H, Ibbotson SH, Chowdhury MM, Beck MH, Bourke J, English J, Farr P, Foulds IS, Gawkrodger DJ, George S, Orton DI, Shaw S, McFadden J, Norris P, Podmore P, Powell S, Rhodes LE, Sansom J, Wilkinson M, van Weelden H, Ferguson J. Photopatch testing of 1155 patients: results of the U.K. multicentre photopatch study group. Br J Dermatol. 2006;155(4):737–47.CrossRefPubMedGoogle Scholar
- 35.Green A, Williams G, Neale R, Hart V, Leslie D, Parsons P, Marks GC, Gaffney P, Battistutta D, Frost C, Lang C, Russell A. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet. 1999;354(9180):723–9.CrossRefPubMedGoogle Scholar